Repositioning Candidate Details
| Candidate ID: | R0982 |
| Source ID: | DB06326 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Latiglutenase |
| Synonyms: | Latiglutenase |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | -- |
| CAS Number: | 1360452-96-5 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous) and autoimmune diseases such as celiac disease. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | ALV003 is an orally administered combination of two proteases engineered to digest gluten. It targets the glutamine and proline residues that are common in gluten. ALV003 consists of a glutamine-specific cysteine protease (EP-B2) and a proline specific prolyl endopeptidase (PEP). The proposed mechanism of action of ALV003 is to digest gluten into non-immunotoxic fragments. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|